Fiets R B, Staal A H J, Cramer G E, Blijlevens N M A
Department of Hematology, Erasmus University Medical Center, Rotterdam, the Netherlands.
Neth J Med. 2018 Sep;76(7):330-335.
Tyrosine kinase inhibitors (TKIs) have changed the landscape of treatment for patients with chronic myeloid leukemia (CML) leading to a life expectancy comparable to the general population. Side effects commonly encountered during TKI treatment are pleural effusion due to use of dasatinib and vascular side effects due to nilotinib and ponatinib. Coronary artery spasm (CAS), although encountered during treatment with other chemotherapeutic drugs, have to our knowledge never been reported during TKI treatment. Here, we describe two cases of coronary artery spasms which are likely due to TKIs.
酪氨酸激酶抑制剂（TKIs）改变了慢性髓性白血病（CML）患者的治疗格局，使患者预期寿命与普通人群相当。TKI治疗期间常见的副作用是使用达沙替尼导致的胸腔积液，以及使用尼洛替尼和波纳替尼导致的血管副作用。冠状动脉痉挛（CAS）虽然在使用其他化疗药物治疗期间会出现，但据我们所知，在TKI治疗期间从未有过相关报道。在此，我们描述两例可能由TKIs引起的冠状动脉痉挛病例。
